Table 6 Clinical features for patients... | American Society of Hematology

Table 6

Clinical features for patients in LY10 and LY06 (risk group defined as in LY10)

	LY10 CODOX-M/IVAC study patients, risk group defined as in LY10				LY06 patients, risk group defined as in LY10
	Low risk, N = 24		High risk, N = 62		Low risk, N = 24		High risk, N = 39
	n	%	n	%	n	%	n	%
Risk group defined as in LY06
Low risk	NA		NA		15	63	0	0
High risk	NA		NA		9	38	39	100
Median age, y (range)	38	(20-56)	39	(17-60)	32	(15-59)	43	(17-60)
Sex
Male	20	83	47	76	17	71	22	56
Female	4	17	15	24	7	29	17	44
Ann Arbor stage
I	16	67	0	0	13	54	0	0
II	8	33	4	6	9	38	3	8
III	0	0	7	11	2	8	6	15
IV	0	0	51	82	0	0	30	77
WHO PS
0	14	58	12	19	21	88	6	15
1	10	42	17	27	3	13	11	28
2	0	0	17	27	0	0	14	36
3	0	0	14	23	0	0	6	15
4	0	0	2	3	0	0	2	5
LDH level
Normal	17	71	1	2	22	92	2	5
Raised	7	29	61	98	2	8	37	95
IPI
0	17	71	0	0	20	83	0	0
1	7	28	2	3	4	17	0	0
2	0	0	30	48	0	0	22	56
3	0	0	30	48	0	0	17	44

	LY10 CODOX-M/IVAC study patients, risk group defined as in LY10				LY06 patients, risk group defined as in LY10
	Low risk, N = 24		High risk, N = 62		Low risk, N = 24		High risk, N = 39
	n	%	n	%	n	%	n	%
Risk group defined as in LY06
Low risk	NA		NA		15	63	0	0
High risk	NA		NA		9	38	39	100
Median age, y (range)	38	(20-56)	39	(17-60)	32	(15-59)	43	(17-60)
Sex
Male	20	83	47	76	17	71	22	56
Female	4	17	15	24	7	29	17	44
Ann Arbor stage
I	16	67	0	0	13	54	0	0
II	8	33	4	6	9	38	3	8
III	0	0	7	11	2	8	6	15
IV	0	0	51	82	0	0	30	77
WHO PS
0	14	58	12	19	21	88	6	15
1	10	42	17	27	3	13	11	28
2	0	0	17	27	0	0	14	36
3	0	0	14	23	0	0	6	15
4	0	0	2	3	0	0	2	5
LDH level
Normal	17	71	1	2	22	92	2	5
Raised	7	29	61	98	2	8	37	95
IPI
0	17	71	0	0	20	83	0	0
1	7	28	2	3	4	17	0	0
2	0	0	30	48	0	0	22	56
3	0	0	30	48	0	0	17	44